

What is the Drug Wastage Program?	 Effective January 1, 2024, the Drug Wastage Program is an expansion of the voluntary program managed by Prime Therapeutics for Blue Cross. This program identifies specific authorizations for a targeted list of drugs. It requires rounding the dosage down (within 10% of the requested dose) to allow for more efficient vialsize utilization when clinically appropriate. This program is designed to reduce waste, improve the efficiency of healthcare, and provide high-quality patient care. The practice of rounding doses when they are within this 10% threshold is supported by the Hematology/Oncology Pharmacy Association (HOPA), National Comprehensive Cancer Network (NCCN), and the American Society of Clinical Oncology (ASCO). A reduction in dose within 10% of the requested dose should not result in a clinically meaningful difference in the efficacy of the therapeutic product.
Who is Prime Therapeutics?	Prime Therapeutics is an independent company that specializes in managing provider-administered drugs covered under the medical benefit. Prime began managing oncology drugs effective January 1, 2024.
How will my patients be impacted by the Drug Wastage Program on January 1, 2024?	No patient impact is anticipated.
How will providers be impacted by the Drug Wastage Program?	 Prime will contact providers after they submit a precertification request for drugs included in this program if the particular case would require a dose rounding adjustment. Dose rounding ultimately eases the compounding process for pharmacy personnel. Providers can appeal the determination to round the dose down to the nearest vial size when within 10% of the requested dose if the patient medically requires the higher dose. Appeals can be made to Prime at 1-800-424-8270. If a dose or frequency changes during the course of therapy, providers should contact Prime at 1-800-424-8270 to update the authorization in order to receive appropriate reimbursement.
How were providers notified of this program?	This announcement was posted on Provider News and sent via Provider Notify in September 2023.

Blue Cross and Blue Shield of Alabama is an independent licensee of the Blue Cross and Blue Shield Association. Prime Therapeutics LLC is an independent company contracted by Blue Cross and Blue Shield of Alabama to provide pharmacy benefit management services.